AbbVie Inc. Acquisitions, Net of Cash Acquired
AbbVie Inc. (ABBV) reported Acquisitions, Net of Cash Acquired of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired · last filed 2026-08-03
- AbbVie Inc. payments to acquire businesses, net of cash acquired for the quarter ending 2026-06-30 was $0.00.
- AbbVie Inc. payments to acquire businesses, net of cash acquired for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- AbbVie Inc. payments to acquire businesses, net of cash acquired for the quarter ending 2025-12-31 was $0.00.
- AbbVie Inc. payments to acquire businesses, net of cash acquired for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- AbbVie Inc. payments to acquire businesses, net of cash acquired for fiscal 2025 was $204.00M, a 98.83% decline from fiscal 2024.
- AbbVie Inc. payments to acquire businesses, net of cash acquired for fiscal 2024 was $17.49B.
- AbbVie Inc. payments to acquire businesses, net of cash acquired for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- AbbVie Inc. payments to acquire businesses, net of cash acquired for fiscal 2022 was $255.00M, a 51.43% decline from fiscal 2021.
| Period end | Payments to Acquire Businesses, Net of Cash Acquired 3 month | Payments to Acquire Businesses, Net of Cash Acquired 6 month | Payments to Acquire Businesses, Net of Cash Acquired 9 month | Payments to Acquire Businesses, Net of Cash Acquired 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $0.00 10-Q · filed 2026-08-03 | $0.00 derived: sum of 3 quarters · filed 2026-08-03 | $0.00 derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-05-08 | $0.00 derived: sum of 3 quarters · filed 2026-05-08 | $0.00 derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $0.00 derived: sum of 2 quarters · filed 2026-02-20 | $0.00 derived: sum of 3 quarters · filed 2026-08-03 | $204.00M 10-K · filed 2026-02-20 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2026-08-03 | $204.00M 10-Q · filed 2025-11-04 | $204.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $204.00M 10-Q · filed 2026-08-03 | $204.00M derived: sum of 3 quarters · filed 2026-08-03 | $8.50B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $204.00M 10-Q · filed 2026-05-08 | $204.00M derived: sum of 2 quarters · filed 2026-05-08 | $8.50B derived: sum of 3 quarters · filed 2026-05-08 | $8.50B derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $8.29B derived: sum of 2 quarters · filed 2026-02-20 | $8.29B derived: sum of 3 quarters · filed 2026-02-20 | $17.49B 10-K · filed 2026-02-20 |
| 2024-09-30 | $8.29B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $8.29B derived: sum of 2 quarters · filed 2025-11-04 | $17.49B 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $9.20B 10-Q · filed 2025-08-04 | ||
| 2024-03-31 | $9.20B 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-20 | |||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-04 | $0.00 derived: sum of 2 quarters · filed 2024-11-04 | $0.00 derived: sum of 3 quarters · filed 2024-11-04 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-07 | $0.00 derived: sum of 2 quarters · filed 2024-08-07 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-03 | |||
| 2022-12-31 | $255.00M 10-K · filed 2025-02-14 | |||
| 2021-12-31 | $525.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $525.00M derived: sum of 2 quarters · filed 2024-02-20 | $525.00M 10-K · filed 2024-02-20 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $0.00 10-Q · filed 2021-11-02 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-02 | |||
| 2020-12-31 | $122.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $122.00M derived: sum of 2 quarters · filed 2023-02-17 | $38.26B 10-K · filed 2023-02-17 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $38.14B 10-Q · filed 2021-11-02 | ||
| 2020-06-30 | $38.14B 10-Q · filed 2021-08-02 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $0.00 derived: sum of 2 quarters · filed 2022-02-18 | $0.00 10-K · filed 2022-02-18 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $0.00 10-Q · filed 2020-11-04 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-04 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-19 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $0.00 derived: sum of 2 quarters · filed 2018-02-16 | $0.00 10-K · filed 2018-02-16 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $0.00 10-Q · filed 2017-11-07 | ||
| 2017-06-30 | $0.00 10-Q · filed 2017-08-07 | |||
| 2016-12-31 | $18.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $40.00M derived: sum of 2 quarters · filed 2019-02-27 | $2.47B derived: sum of 3 quarters · filed 2019-02-27 | $2.50B 10-K · filed 2019-02-27 |
| 2016-09-30 | $22.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $2.45B derived: sum of 2 quarters · filed 2017-11-07 | $2.48B 10-Q · filed 2017-11-07 | $2.48B derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-06-30 | $2.43B derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $2.46B 10-Q · filed 2017-08-07 | $2.46B derived: sum of 3 quarters · filed 2018-02-16 | $2.46B derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-03-31 | $28.00M 10-Q · filed 2016-05-06 | $28.00M derived: sum of 2 quarters · filed 2018-02-16 | $28.00M derived: sum of 3 quarters · filed 2018-02-16 | $10.78B derived: sum of 4 quarters · filed 2018-02-16 |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $0.00 derived: sum of 2 quarters · filed 2018-02-16 | $10.75B derived: sum of 3 quarters · filed 2018-02-16 | $11.49B 10-K · filed 2018-02-16 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $10.75B derived: sum of 2 quarters · filed 2016-11-07 | $11.49B 10-Q · filed 2016-11-07 | $11.54B derived: sum of 4 quarters · filed 2016-11-07 |
| 2015-06-30 | $10.75B derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $11.49B 10-Q · filed 2016-08-05 | $11.54B derived: sum of 3 quarters · filed 2016-08-05 | $12.09B derived: sum of 4 quarters · filed 2016-08-05 |
| 2015-03-31 | $736.00M 10-Q · filed 2016-05-06 | $786.00M derived: sum of 2 quarters · filed 2016-05-06 | $1.34B derived: sum of 3 quarters · filed 2016-05-06 | |
| 2014-12-31 | $50.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-20 | $605.00M derived: sum of 2 quarters · filed 2015-02-20 | $622.00M 10-K · filed 2015-02-20 | |
| 2014-09-30 | $555.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $572.00M 10-Q · filed 2014-11-07 | ||
| 2014-06-30 | $17.00M 10-Q · filed 2014-08-07 | |||
| 2013-12-31 | $47.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-20 | $271.00M derived: sum of 2 quarters · filed 2015-02-20 | $405.00M derived: sum of 3 quarters · filed 2015-02-20 | $405.00M 10-K · filed 2015-02-20 |
| 2013-09-30 | $224.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $358.00M derived: sum of 2 quarters · filed 2014-11-07 | $358.00M 10-Q · filed 2014-11-07 | $266.00M derived: sum of 4 quarters · filed 2015-02-20 |
| 2013-06-30 | $134.00M 10-Q · filed 2013-08-09 | $134.00M 10-Q · filed 2014-08-07 | $42.00M derived: sum of 3 quarters · filed 2015-02-20 | $42.00M derived: sum of 4 quarters · filed 2015-02-20 |
| 2013-03-31 | $0.00 10-Q · filed 2013-05-08 | -$92.00M derived: sum of 2 quarters · filed 2015-02-20 | -$92.00M derived: sum of 3 quarters · filed 2015-02-20 | $17.00M derived: sum of 4 quarters · filed 2015-02-20 |
| 2012-12-31 | -$92.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-20 | -$92.00M derived: sum of 2 quarters · filed 2015-02-20 | $17.00M derived: sum of 3 quarters · filed 2015-02-20 | $688.00M 10-K · filed 2015-02-20 |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $109.00M derived: sum of 2 quarters · filed 2013-11-12 | $780.00M 10-Q · filed 2013-11-12 | |
| 2012-06-30 | $109.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $780.00M 10-Q · filed 2013-08-09 | ||
| 2012-03-31 | $671.00M 10-Q · filed 2013-05-08 | |||
| 2011-12-31 | $273.00M 10-K · filed 2014-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |